论文部分内容阅读
氯吡格雷通过拮抗血小板腺苷二磷酸(ADP)受体P2Y12,在急性冠状动脉综合征治疗中发挥重要作用,但部分患者存在药物抵抗现象。目前尚无特异性检测指标和统一定义,多以基础状态和服药后ADP诱导血小板聚集率差值≤10%作为抵抗标准;此现象发生率尚不明确,与临床血栓形成关系仅有小样本试验证实;机制方面国内外学者提出遗传因素、药物相互作用、基础疾病及胰岛素抵抗等多项可能,治疗方面目前尚无特效方法。
Clopidogrel plays an important role in the treatment of acute coronary syndromes by antagonizing the platelet adenosine diphosphate (ADP) receptor P2Y12, but some patients have a drug resistance phenomenon. There is no specific test indicators and uniform definition, and more based on the state and after taking ADP-induced platelet aggregation rate difference ≤ 10% as a resistance standard; the incidence of this phenomenon is not yet clear, and clinical thrombosis only small sample test Confirmed; mechanism scholars at home and abroad put forward a number of genetic factors, drug interactions, underlying diseases and insulin resistance and many other possible treatment there is no specific method.